middle.news
Neurizon Secures $5M to Propel ALS Drug into Pivotal Trial
9:33am on Thursday 18th of September, 2025 AEST
•
Biotechnology
Read Story
Neurizon Secures $5M to Propel ALS Drug into Pivotal Trial
9:33am on Thursday 18th of September, 2025 AEST
Key Points
Institutional placement raises $5 million at $0.12 per share
Board and management to subscribe additional $0.2 million, partly subject to shareholder approval
Funds earmarked for HEALEY ALS Platform Trial entry in Q4 2025, pending FDA IND clearance
Proceeds to support GMP manufacturing, regulatory filings, and pre-clinical programs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE